Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.64 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.64 |
| ▸ | HTR2B | P41595 | 3/20 | 0.59 |
| ▸ | HTR2A | P28223 | 2/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10670278 | 0.85 | MTNR1A (0.60) | MTNR1AMTNR1BHTR2BHTR2AHTR2C | |
| SCHEMBL30777142 | 0.84 | MTNR1A (0.58) | MTNR1AMTNR1BHTR2BHTR2AHTR2C | |
| SCHEMBL24723323 | 0.84 | MTNR1A (0.58) | MTNR1AMTNR1BHTR2BHTR2AHTR2C | |
| SCHEMBL15389130 | 0.83 | SPR (0.47) | MTNR1AMTNR1BHTR2AHTR2CKDM4E | |
| SCHEMBL28710170 | 0.83 | NR4A2 (0.58) | MTNR1AMTNR1BNR4A2 | |
| SCHEMBL9790365 | 0.83 | MTNR1A (0.55) | MTNR1AMTNR1BHTR2BHTR2AHTR2C | |
| SCHEMBL10565825 | 0.82 | MTNR1A (0.56) | MTNR1AMTNR1BHTR2BHTR2AHTR2C | |
| Indorenate SCHEMBL10080621 | 0.82 | HTR2B (0.64) | MTNR1AMTNR1BHTR2BHTR2AHTR2C | |
| SCHEMBL10299457 | 0.81 | GABRA1 (0.53) | MTNR1AMTNR1B | |
| Indorenate SCHEMBL10566582 | 0.81 | HTR2B (0.63) | MTNR1AMTNR1BHTR2BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210251960-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2021-08-19 | — | — | US | disclosed |
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2019-11-21 | — | — | US | disclosed |
| US-10398678-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3078374-B1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | UNIV VANDERBILT (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20180271835-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2018-09-27 | — | — | US | disclosed |
| US-9895351-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160303082-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY | 2016-10-20 | — | — | US | disclosed |
| EP-3078374-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9346803-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-12-18 | — | — | US | disclosed |
| EP-2768499-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013059245-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | MTNR1A 520/4885MTNR1B 1060/4885HTR2B 4208/4885 |
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | MTNR1A 520/4885MTNR1B 1060/4885HTR2B 4208/4885 |
| US-20180271835-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | MTNR1A 520/4885MTNR1B 1060/4885HTR2B 4208/4885 |
| US-10398678-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | MTNR1A 520/4885MTNR1B 1060/4885HTR2B 4208/4885 |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | MTNR1A 426/4885MTNR1B 892/4885HTR2B 4330/4885 |
| US-20210251960-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | MTNR1A 520/4885MTNR1B 1060/4885HTR2B 4208/4885 |
| US-20160303082-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | MTNR1A 520/4885MTNR1B 1060/4885HTR2B 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.